When Can We Expect A Profit From Imricor Medical Systems, Inc. (ASX:IMR)?

Imricor Medical Systems, Inc. (ASX:IMR) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. On 31 December 2024, the AU$471m market-cap company posted a loss of US$30m for its most recent financial year. Many investors are wondering about the rate at which Imricor Medical Systems will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Imricor Medical Systems is bordering on breakeven, according to some Australian Medical Equipment analysts. They anticipate the company to incur a final loss in 2026, before generating positive profits of US$15m in 2027. Therefore, the company is expected to breakeven roughly 2 years from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 89%, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

Given this is a high-level overview, we won’t go into details of Imricor Medical Systems' upcoming projects, but, keep in mind that by and large a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.

Check out our latest analysis for Imricor Medical Systems

One thing we would like to bring into light with Imricor Medical Systems is it currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

There are key fundamentals of Imricor Medical Systems which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Imricor Medical Systems, take a look at Imricor Medical Systems' company page on Simply Wall St. We've also put together a list of important aspects you should further examine:

1. Valuation: What is Imricor Medical Systems worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Imricor Medical Systems is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Imricor Medical Systems’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.